One of the objectives in designing a downstream process for
biopharmaceutical products is to remove any possible contaminating
proteins, including host cell proteins (HCPs). HCPs can still be present
at significant concentrations following several purification steps and
can even be co-purified and concentrated with the drug substance itself.
Multiple purification steps may be needed to remove HCPs,
however, each purification step also has the potential for additional
loss of product. Therefore, during the development of a downstream
process, suitable assays must be available to determine both the
concentration of the product and the amount of HCP present.
The type of assay required to determine HCP
concentration is dependent upon the phase of product development. In the
early process development phase as well as in early clinical phases,
generic assays are normally acceptable. Charles River offers generic host cell protein assays for E. coli
and CHO-derived products. These assays have been developed and
validated on a generic sample matrix. They may be useful in the early
stages of process development for a general investigation into HCP
burden. Additionally, kits on any kind of cell systems may be used and
adapted for a client matrix as well.
However, once the biopharmaceutical
is used in clinical phase III studies, a validated, product-specific HCP
assay is normally required. We have developed many specific
assays on different cell matrices to quantify HCP using either ILA or
ELISA. Assay development starts with testing for a suitable, specific
antigen which has been produced by our client. This antigen will be used
to immunize the animals from which the antisera will be obtained. After
purification and qualification of the antibodies, a specific detection
system is developed and optimized for the specific matrix. According
to regulatory authorities, the assay should be validated prior to use
in the quality control of a biopharmaceutical. The development and
validation of a client-specific HCP assay normally requires between six
and twelve months. Therefore, development of the assay should begin as
soon as the downstream process development has been finalized.
No comments:
Post a Comment